{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"84","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Estimated using the Kaplan-Meier methods.\n\nProgression is defined using the revised IWG response criteria, as any new lesion or increase by ≥50% of previously involved sites from nadir.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with Granulocyte-Colony Stimulating Factor (G-CSF) and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplantation. Patients receive standard myeloablative conditioning followed by autologous Peripheral Blood Stem Cell Transplant (PBSCT). Patients then undergo infusion of ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR) on day 2 or 3 after transplantation.\n\nperipheral blood stem cell transplantation (PBSCT): Undergo autologous PBSCT\n\nfilgrastim: Given IV\n\npolymerase chain reaction: Correlative studies\n\nrituximab: Given IV\n\ngenetically engineered lymphocyte therapy: Receive ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR)\n\nlaboratory biomarker analysis: Correlative studies\n\nplerixafor: Given IV\n\nautologous hematopoietic stem cell transplantation: Undergo autologous PBSCT","id":"OG000","title":"Treatment (Cellular Adoptive Immunotherapy Following PBSCT)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Progression-free Survival at 1 Year","type":"SECONDARY","unitOfMeasure":"percentage of participants"}